Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
Nehad M. Ayoub,Kamal M Al-Shami,Rami J. Yaghan +2 more
- Vol. 11, pp 53-69
Reads0
Chats0
TLDR
The immune microenvironment of HER2-positive breast cancer is described and recent clinical advances of immunotherapeutic treatments in this breast cancer subtype are summarized and rationale and ongoing clinical evidence to the use of immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy are provided.Abstract:
Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather heterogeneous. Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) have shown evidence of immunogenicity based on tumor-immune interactions. Several preclinical and clinical studies have explored the potential for immunotherapy to improve the clinical outcomes for different subtypes of breast cancer. This review describes the immune microenvironment of HER2-positive breast cancer and summarizes recent clinical advances of immunotherapeutic treatments in this breast cancer subtype. The review provides rationale and ongoing clinical evidence to the use of immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy in breast cancer. In addition, the present paper describes the most relevant clinical progress of strategies for the combination of immunotherapy with standard treatment modalities in HER2-positive breast cancer including chemotherapy, targeted therapy, and radiotherapy.read more
Citations
More filters
Journal ArticleDOI
Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer
TL;DR: Current research focused on PTX, its evaluations in preclinical research and application clinical practice as well as the perspective of the drug for future implication in BC therapy are summarized.
Journal ArticleDOI
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Vikas Jain,Hitesh Kumar,Haritha V. Anod,Pallavi Chand,N. Vishal Gupta,Surajit Dey,Siddharth S. Kesharwani +6 more
TL;DR: The application of nanomedicine including CRISPR nanoparticle, exosomes for the treatment of BC/TNBC and other molecular targets available such as poly (ADP-ribose) polymerase (PARP), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc. for further exploration have been discussed.
Journal ArticleDOI
Nano-Enhanced Drug Delivery and Therapeutic Ultrasound for Cancer Treatment and Beyond.
TL;DR: This review discusses the application of high intensity focus ultrasound for non-invasive tumor ablation and immunomodulatory effects of ultrasound, as well as the efficacy of nanoparticle-enhanced ultrasound therapies for different medical conditions.
Journal ArticleDOI
Immunotherapy: A Challenge of Breast Cancer Treatment.
TL;DR: Current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherAPies are summarized.
Journal ArticleDOI
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
Sara Verdura,Elisabet Cuyàs,Eric Cortada,Joan Brunet,Eugeni López-Bonet,Begoña Martin-Castillo,Joaquim Bosch-Barrera,José Antonio Encinar,Javier A. Menendez +8 more
TL;DR: Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, it is found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes that modulate N-linked glycan decoration of PD- L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD -L1.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.